Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | XPO1 | O14980 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25485509 | 0.91 | RAPGEF4 (0.46) | CES2ARMAPTMEN1KMT2A | |
| SCHEMBL7216715 | 0.83 | CES2 (0.48) | CES2ARMAPTMEN1KMT2A | |
| SCHEMBL440959 | 0.78 | CES2 (0.58) | CES2MAPTIDO1RXRARXRB | |
| SCHEMBL16234266 | 0.77 | CES2 (0.46) | CES2ARMAPTIDO1RXRA | |
| SCHEMBL22861023 | 0.77 | GABRB2 (0.52) | CES2ARMAPTIDO1RAPGEF4 | |
| SCHEMBL1104677 | 0.77 | GABRB2 (0.52) | CES2ARMAPTIDO1RAPGEF4 | |
| SCHEMBL25485527 | 0.77 | GABRA1 (0.60) | MAPTMEN1KMT2ARXRARXRB | |
| SCHEMBL25489518 | 0.77 | CES2 (0.52) | CES2ARMAPTIDO1RXRA | |
| SCHEMBL19130784 | 0.75 | TSHR (0.50) | CES2MAPTMEN1KMT2A | |
| SCHEMBL19124474 | 0.75 | TSHR (0.50) | CES2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | NOVARTIS AG (CH) | 2019-08-20 | — | — | US | disclosed |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | NOVARTIS PHARMA AG (CH) | 2018-01-25 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385004-B2 | Process and intermediates for the preparation of NEP inhibitors | MME, ACE, REN | CES2 1630/4885AR 1038/4885MAPT 326/4885 |
| US-20180022690-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF NEP INHIBITORS | MME, ACE, REN | CES2 1630/4885AR 1038/4885MAPT 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.